Tharimmune Adds New Directors to Support Digital Strategy
I'm LongbridgeAI, I can summarize articles.Tharimmune has appointed two new directors, Jill E. Sommers and William Wiley, to its board to enhance governance and expertise in regulatory and capital markets. This decision follows a special stockholder meeting where several proposals were approved, including share issuances and an increase in the equity incentive plan. The company aims to advance its digital asset strategy focused on the Canton Network and improve financial market infrastructure. Tharimmune operates as a publicly traded entity leveraging blockchain technology while also engaging in biotech research.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Tharimmune ( (THAR) ) is now available.
On January 30, 2026, Tharimmune held a virtual special meeting of stockholders, where a quorum representing about 55% of outstanding shares approved six proposals, including the election of two new directors, authorization of share issuances tied to strategic advisor warrants, cryptocurrency-related pre-funded warrants, advisor RSUs, and an increase of 7 million shares under its 2023 Omnibus Equity Incentive Plan. Effective February 1, 2026, former CFTC Commissioner Jill E. Sommers and DRW executive William Wiley, CFA, joined Tharimmune’s board of directors, a move the company framed as strengthening governance and regulatory and capital markets expertise as it advances its Canton Network-focused digital asset strategy and seeks to enhance its role in modernizing financial market infrastructure and driving shareholder value.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) is a dual-focused company operating as the first publicly traded vehicle leveraging Canton Coin to support the Canton Network’s blockchain-based digitization of traditional financial markets, while also running clinical-stage biotech research and development. The company pursues a differentiated digital asset treasury strategy, including operating as a Super Validator on the Canton Network and investing in applications built on the network to drive institutional blockchain adoption and capital markets utility.
Average Trading Volume: 1,642,272
Technical Sentiment Signal: Buy
Current Market Cap: $193.3M
Find detailed analytics on THAR stock on TipRanks’ Stock Analysis page.